An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting  by Kishihara, Jun et al.
Journal of Arrhythmia 32 (2016) 67–69Contents lists available at ScienceDirectJournal of Arrhythmiahttp://d
1880-42
n Corr
versity
Japan. T
E-mjournal homepage: www.elsevier.com/locate/joaCase ReportAn appropriate shock of the wearable cardioverter-deﬁbrillator
in an outpatient setting
Jun Kishihara, MD, Shinichi Niwano, MDn, Hironori Nakamura, MD, Tazuru Igarashi, MD,
Naruya Ishizue, MD, Tamami Fujiishi, MD, Jun Oikawa, MD, Masami Murakami, MD,
Hidehira Fukaya, MD, Junya Ako, MD
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japana r t i c l e i n f o
Article history:
Received 25 June 2015
Received in revised form
4 August 2015
Accepted 14 August 2015
Available online 26 September 2015
Keywords:
Wearable cardioverter-deﬁbrillator
Sudden cardiac death
Ventricular tachycardia
Ventricular ﬁbrillationx.doi.org/10.1016/j.joa.2015.08.003
76/& 2015 Japanese Heart Rhythm Society. Pu
espondence to: Department of Cardiovascu
School of Medicine 1-15-1 Kitasato, Minam
el.: þ81 42 778 8111; fax: þ81 42 778 8441.
ail address: shniwano@med.kitasato-u.ac.jp (Sa b s t r a c t
The wearable cardioverter-deﬁbrillator (WCD) represents an alternative clinical approach to prevent
sudden cardiac death as a bridge to therapy when making a ﬁnal decision regarding the need for an
implantable cardioverter deﬁbrillator (ICD), especially in patients who are in the so-called gray zone
according to ICD guidelines. Although the WCD system was introduced in Japan in April 2014, data
regarding its usage and experience are limited. We report the ﬁrst case of appropriate shock therapy
using the WCD in an outpatient setting in Japan. We describe the case of a 22-year-old-woman who
received the ﬁrst case of successful appropriate WCD shock therapy in an outpatient setting in Japan.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The wearable cardioverter-deﬁbrillator (WCD; LifeVest 4000, ZOLL,
Pittsburgh, PA, USA) is designed to automatically detect and treat life-
threatening ventricular tachycardia/ﬁbrillation (VT/VF) by delivering a
biphasic electrical shock through body-surface patches. Although a
speciﬁc surgical technique is not required for implantation, as with
the implantable cardioverter deﬁbrillator (ICD) system, the WCD
detects and terminates VT/VF with a high sensitivity and speciﬁcity
almost comparable to those of the ICD system [1]. Although the
continuous wearing of a speciﬁc WCD jacket system limits the
patient’s quality of life and may render the device unsuitable for long-
term usage, its proﬁle should be useful as a bridge to ICD therapy,
especially in patients who are in the so-called gray zone according to
ICD guidelines. The WCD system has been used worldwide, and its
clinical applications have been documented in several reports [2,3].
TheWCDwas introduced in Japan in April 2014, but data regarding its
usage and experience are limited [4]. Here, we report a case in which
appropriate shock therapy was applied using the WCD in an out-
patient setting. To the best of our knowledge, this is the ﬁrst such case
reported to date.blished by Elsevier B.V. All rights
lar Medicine, Kitasato Uni-
i-ku, Sagamihara 252-0374,
. Niwano).2. Case
A 22-year-old woman presented to our institute due to serious left
ventricular dysfunction (echocardiographic left ventricular ejection
fraction, 22%) and was admitted to our hospital for the purpose of
diagnosis and introduction of medical treatment. At the time of
admission, she had never experienced palpitations, syncope, or
shortness of breath. During hospitalization, she had a spontaneous VT
attack (230 beats/min) that subsequently changed to VF. Emergent
therapy including external deﬁbrillation successfully terminated the
VT/VF without any complications. Subsequent examinations including
catheterization and coronary angiography revealed no stenosis, and
idiopathic dilated cardiomyopathy was diagnosed. The ICD guidelines
indicated that this patient was class I; however, the patient and her
family did not immediately accept our therapeutic recommendation,
despite the fact that they seemed to be rational and highly educated.
They strongly hoped to calmly discuss treatment options in their own
at their home. We advised that this type of postponement was not
recommended. Fortunately, we offered the WCD as an alternative risk
control method and suggested that the patient consider this option. In
addition, some stenosis of the celiac artery was noted, and the
superior mesenteric artery and left renal artery were detected in
3-dimensional computed tomography scanning. Although magnetic
resonance imaging (MRI) was recommended for further diagnosis, it
could not be immediately scheduled. ICD implantationwas postponed
due to this MRI scheduling issue, because 3-T MRI is not possible after
ICD implantation. WCD proﬁles were set as follows: VT rate threshold,reserved.
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response time, 25 s; delivery energy settings, 150 J (5 times). Educa-
tion and training about the wearing of a WCD were provided by our
WCD training team, which includes doctors, nurses, and medical
engineers, and the patient was discharged from the hospital after
completing this training course. During WCD education and training,
we prescribed several antiarrhythmic agents and anti-heart failure
agents such as amiodarone (100 mg/day), carvedilol (20 mg/day),
perindopril (2 mg/day), and spironolactone (25 mg/day). We also
prescribed cardiac rehabilitation including exercise stress testing (7
metabolic equivalents), which showed no episodes of arrhythmic
events.
Twelve days after hospital discharge, the patient experienced chest
discomfort and palpitations after taking her dog for a walk. While she
was experiencing those symptoms, the WCD records showed inces-
sant, non-sustained VT and subsequent VF (Fig. 1). During the initial
VT sequence, VT was detected at the ﬁrst red arrow (grid #29), and
the patient canceled the shock therapy sequence because she had not
yet fallen into unconsciousness (second red arrow at grid #86).
However, a subsequent VF rendered her unconscious, and a 150-J
shock was delivered and eliminated VT/VF (third red arrow at grid
#116). She did not feel any pain at the time of shock delivery, probably
because she lost consciousness during this period. During this epi-
sode, a patient’s family member was standing nearby, but he followed
the rules and did not touch her during theWCD therapeutic sequence.
This choice kept him safe, avoiding unnecessary injury due to shock.
After this event, the patient was readmitted to our hospital until the
time of her scheduled MRI and ﬁnal ICD implantation. Sporadic non-
sustained VT was suppressed by intravenous administration of nife-
kalant, and 100 mg amiodarone daily was changed to 320mg sotalol
daily. Finally, an ICD was implanted 7 days after WCD shock delivery
without any complications.VT detection
Response buttons
Shock delivery
Fig. 1. ECG recording of channel ‘SS’ in WCD during the shock episode. The shock
sequence was once canceled by the patient with the response buttons 56 s after VT
detection (A), but 150 J shock was delivered after 30 s because of subsequent VF
detection, then it ﬁnally recovered sinus rhythm (B).3. Discussion
The main indication for theWCD is as a bridge to ICD implantation
in patients at temporal risk of sudden cardiac death in the subacute
phase of acute myocardial damage, those with accepted indicators for
ICD implantation but also temporal contraindication factors (e.g.,
infection), or those waiting for a ﬁnal decision regarding ICD
implantation [5]. In our case, idiopathic dilated cardiomyopathy with
severe left ventricular dysfunction and documented spontaneous VT/
VF was diagnosed, so she was considered to have a class I indication
for ICD implantation [6]. However, she did not immediately accept
this therapeutic recommendation because she was young and wanted
to discuss her future plans with her family in the comfort of her own
home while waiting to undergo a scheduled MRI. Fortunately, we
offered the WCD as a therapeutic option and facilitated its use in an
outpatient setting. Eventually, the device saved her life, and this epi-
sode encouraged her to accept the fact that ICD implantation was her
best therapeutic option. Various conditions can lead to a waiting
period for ICD therapy, not only during hospitalization but also under
outpatient conditions. The WCD might be a useful therapeutic tool
that is safer that plain monitoring during this waiting period.
To prevent inappropriate WCD shock, the patient can cancel the
shock sequence by pushing response buttons. This feature worked
well in the present case. A shock delivered during repeated non-
sustained VT while the patient is still conscious, which might have
been inappropriate in this case, can thus be avoided. Eventually,
this sequence led to subsequent VF, which was successfully ter-
minated by the WCD. Because VF caused unconsciousness, the
patient did not experience any pain due to the shock. These
properties are similar to those of the ICD system, suggesting that
the WCD can replace the ICD, at least for the purpose of preventing
sudden death due to VT/VF.
Some features of the WCD are different from an ICD. First, anti-
tachycardia pacing is not available in the WCD system. This patient
had a VT episode resulting in VF, and the antitachycardia pacing might
have been useful to avoid shock therapy. This is one limitation of the
WCD system. Second, bystanders around the patient must be careful
to avoid shock delivery. Because shock energy of the WCD is much
higher than that of the ICD, which is similar to an external deﬁ-
brillator, bystanders must not touch a patient wearing a WCD to avoid
electrical injury. This type of accident must be avoided by carefully
educating patients and signiﬁcant friends or family members in an
education program provided by a speciﬁc training team including
nurses and/or medical engineers. This education program also
improves the patient’s understanding and level of comfort with the
device and increases the wearing time in a day, which is essential for
increasedWCD efﬁcacy [7]. The voice announcement that comes from
the WCD before deﬁbrillation begins (i.e., not to touch the patient) is
also incredibly effective to avoid this type of accident. Third, the choice
of an optimally sized jacket and settings of electrodes and patches is
quite important, because ﬁtting these materials to the skin surface is
essential for arrhythmia detection and therapeutic shock delivery [8].
Realistically, a doctor cannot spend enough time to explaining these
practical but important points, but a speciﬁc training team can achieve
adequate an understanding, as mentioned in a statement of the
Japanese Heart Rhythm Society [9]. In this case, the WCD wearing
time was 23.23–23.55 h per day, which represents a good level of
compliance, and the noise alarm was not activated during her use of
the WCD. These good results were probably achieved by our training
program, which is handled by a speciﬁc WCD training team. Because
WCD shock therapy was delivered in an outpatient setting, an
ambulance was called in order to transport the patient to the hospital.
Because the ambulance crew had not received WCD education and
training, they did not recognize the WCD jacket or understand what
kind of therapy was being used. Fortunately, the patient and her
family were able to explain the WCD system to the ambulance crew,
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broader announcement will be needed in the future to avoid inap-
propriate WCD undressing by uninformed bystanders.4. Conclusions
We experienced a case of successful and appropriate WCD shock
therapy in an outpatient setting that is presumably the ﬁrst such case
in Japan. WCD is considered to be effective and safe even in an out-
patient setting, at least for patients who meet speciﬁc conditions.Conﬂict of interest
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